ASND stock news

ASND stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-26 17:59:00 UTC#516459newconfirmednews

Citigroup maintains Buy rating on Ascendis Pharma, cuts price target to $330 from $360

dow_jonesimportance 0.40trust 0.70Ascendis Pharma A/S -0.30Citigroup Inc. 0

2026-10-26 12:00:00 UTC#514564newconfirmednews

Ascendis Pharma reports 5-year sustained kidney function improvements for TransCon PTH in hypoparathyroidism

globenewswireimportance 0.50trust 0.90Ascendis Pharma A/S +0.60TransCon PTH +0.60Elvira Gosmanova 0+2 entities

2026-10-16 12:29:00 UTC#471929newconfirmedpress release

Ascendis Pharma's TransCon CNP receives positive CHMP opinion for achondroplasia treatment in EU

globenewswireimportance 0.60trust 1.00Ascendis Pharma A/S +0.60European Medicines Agency +0.50Committee for Medicinal Products for Human Use +0.50+2 entities

2026-10-16 11:45:00 UTC#471638newconfirmednews

Ascendis Pharma's Yuviwel receives positive CHMP opinion for EU marketing authorization

dow_jonesimportance 0.60trust 0.90Ascendis Pharma A/S +0.70European Medicines Agency +0.50Yuviwel +0.70+1 entities

2026-10-06 13:15:00 UTC#419806newconfirmedpress release

Ascendis Pharma to present 5-year TransCon PTH skeletal data at ASBMR 2026 meeting

globenewswireimportance 0.40trust 0.90Ascendis Pharma A/S +0.30American Society for Bone & Mineral Research +0.20Aliya Khan 0+2 entities

2026-09-30 22:35:33 UTC#394967duplicateconfirmednews

BioMarin and Ascendis Pharma finalize settlement and licensing deal for TransCon CNP, navepegritide, and Yuviwel

reutersimportance 0.30trust 0.90BioMarin Pharmaceutical Inc. +0.40Ascendis Pharma A/S +0.40TransCon CNP +0.40+2 entities

2026-09-30 20:23:00 UTC#394287newconfirmednews

BioMarin, Ascendis Pharma Settle Litigation; Ascendis to Pay Royalties on TransCon CNP Through May 2030

tradingviewimportance 0.50trust 0.80BioMarin Pharmaceutical Inc. +0.40Ascendis Pharma A/S +0.30TransCon CNP +0.20

2026-09-28 09:56:00 UTC#376472newconfirmednews

Cantor Fitzgerald maintains $300 price target on Ascendis Pharma (ASND)

dow_jonesimportance 0.30trust 0.60Ascendis Pharma A/S +0.10Cantor Fitzgerald, L.P. +0.10

2026-09-21 11:28:15 UTC#341878newconfirmednews

Ascendis Pharma approves $400M share buyback and brings TransCon Semaglutide development in-house

tradingviewimportance 0.50trust 0.60Ascendis Pharma A/S +0.60TransCon Semaglutide +0.40

2026-09-15 14:27:19 UTC#314547updateconfirmednews

Ascendis Pharma (ASND) reaffirms €5B 2030 revenue goal, confirms $400M share buyback

quartrimportance 0.50trust 0.70Ascendis Pharma A/S +0.60

2026-09-15 14:02:00 UTC#314405newconfirmednews

Raymond James downgrades Ascendis Pharma (ASND) to Outperform from Strong Buy, maintains $287 price target

dow_jonesimportance 0.40trust 0.70Ascendis Pharma A/S -0.30Raymond James Financial, Inc. -0.30

2026-09-14 22:49:00 UTC#310576duplicateconfirmednews

Ascendis Pharma regains TransCon obesity rights from Novo Nordisk and authorizes share buyback

dow_jonesimportance 0.30trust 0.90Ascendis Pharma A/S +0.60Novo Nordisk A/S -0.20TransCon +0.40+1 entities

2026-09-14 22:34:00 UTC#310547duplicateconfirmednews

Ascendis Pharma Reclaims TransCon Obesity Rights from Novo Nordisk; Board Approves Share Buyback

dow_jonesimportance 0.40trust 0.90Ascendis Pharma A/S +0.50Novo Nordisk A/S -0.30TransCon +0.40+2 entities

2026-09-14 22:01:00 UTC#310407newconfirmedpress release

Ascendis Pharma (ASND) Board Authorizes $400 Million Share Repurchase Program

dow_jonesimportance 0.50trust 0.95Ascendis Pharma A/S +0.40

2026-09-14 22:00:00 UTC#310461newconfirmedpress release

Ascendis Pharma to regain exclusive rights to TransCon metabolic and cardiovascular assets from Novo Nordisk

yahooimportance 0.70trust 1.00Ascendis Pharma A/S +0.50Novo Nordisk A/S -0.30TransCon +0.40+1 entities

2026-09-09 08:23:00 UTC#285384newconfirmednews

Achondroplasia market projected to grow at 11% CAGR through 2036, ResearchAndMarkets report says

yahooimportance 0.30trust 0.50Ascendis Pharma A/S 0BioMarin Pharmaceutical Inc. 0BridgeBio Pharma, Inc. 0+2 entities

2026-09-07 11:22:09 UTC#276122newconfirmednews

BioMarin settles Ascendis patent dispute, closes Alesta Therapeutics acquisition, and receives Jefferies PT hike

tradingviewimportance 0.50trust 0.70BioMarin Pharmaceutical Inc. +0.60Ascendis Pharma A/S +0.40Alesta Therapeutics +0.50+2 entities

2026-09-07 11:22:01 UTC#276145updateconfirmednews

Ascendis Pharma settles BioMarin patent dispute with royalty deal; reACHin trial data set for ESPE 2026

tradingviewimportance 0.40trust 0.70Ascendis Pharma A/S -0.30BioMarin Pharmaceutical Inc. +0.30Morgan Stanley -0.10+2 entities

2026-09-04 16:26:39 UTC#269484newconfirmednews

BioMarin settles patent dispute with Ascendis Pharma, secures 20% U.S. royalties on Yuviwel sales

yahooimportance 0.60trust 0.80BioMarin Pharmaceutical Inc. +0.40Ascendis Pharma A/S -0.20Yuviwel +0.30+2 entities

2026-09-03 20:11:21 UTC#264774newconfirmednews

Canada's Drug Agency recommends conditional reimbursement for Ascendis Pharma's Yorvipath

financial postimportance 0.40trust 0.80Canada's Drug Agency +0.40Ascendis Pharma A/S +0.50Pharmascience Inc. +0.40+2 entities